Ipamorelin Side Effects: What Studies and Users Report

Ipamorelin side effects: what its one placebo-controlled trial found, what users report, the risks of raising growth hormone, and its 2026 FDA and WADA status.

Written by Dr. Andrii Kaleniuk. Updated October 23, 2026.

Ipamorelin is sold as the "gentle" growth hormone peptide, the one with fewer side effects than older options like GHRP-6. Part of that reputation is earned: in its one published placebo-controlled trial, ipamorelin was well tolerated, and in animal studies it raised growth hormone without the cortisol and hunger spikes that older peptides cause. The rest is marketing. Ipamorelin has never been approved for any use, has not been studied long term in healthy adults, and most of what is written about its side effects comes from forums and clinics that sell it.

This guide separates what the studies actually reported from what users describe, explains the risks that come from raising growth hormone itself, and covers ipamorelin's legal and anti-doping status in 2026. It does not include dosing, because no safe dose for bodybuilding has been established.

Ipamorelin Side Effects: The Short Answer

1In the only randomized, placebo-controlled trial (114 surgical patients, up to 7 days), ipamorelin was well tolerated and side effects were no more common than with placebo.
2Commonly reported effects in users: headache, flushing or warmth, dizziness, nausea, water retention, tingling in the hands, increased hunger, and injection-site redness or lumps.
3Effects that come with any sustained rise in growth hormone: fluid retention, joint pain, carpal tunnel symptoms, higher blood sugar and reduced insulin sensitivity.
4Unknowns: there are no long-term safety studies in healthy adults, and no data on cancer risk, heart effects, pregnancy or use under 18.
5Product risk: ipamorelin sold as a "research chemical" is unregulated and may be impure, underdosed or non-sterile.
6Status: not FDA-approved; listed by FDA as a Category 2 compounding substance that may present significant safety risks; banned by WADA under section S2.

What Ipamorelin Is

Ipamorelin is a small synthetic peptide, five amino acids long, that mimics ghrelin, the hormone that makes you hungry. It binds the growth hormone secretagogue receptor in the pituitary gland and triggers a pulse of growth hormone (GH). Its claim to fame, from a 1998 study in rats and pigs, is selectivity: it released GH without significantly raising cortisol (the stress hormone) or ACTH, even at very high doses, unlike the older peptides GHRP-2 and GHRP-6. That selectivity is the basis for the "fewer side effects" reputation. We cover what it is used for in ipamorelin for bodybuilding.

What the Human Studies Reported

Ipamorelin was developed as a drug candidate but never made it to market. The main published human trial tested it for a medical problem, not for muscle:

Published human trial of ipamorelin

Study

Design

What it found on safety

Beck et al., 2014 (Int J Colorectal Dis)

Randomized, placebo-controlled, 114 patients recovering from bowel surgery, intravenous ipamorelin twice daily for up to 7 days

Well tolerated. Any treatment-emergent adverse event: 87.5% with ipamorelin vs 94.8% with placebo. No benefit over placebo for recovery of bowel function.

That is reassuring as far as it goes, but it is a short hospital study in sick patients given the drug intravenously. It says nothing about months of weekly or daily injections in healthy lifters. Earlier small studies in healthy volunteers measured GH release, not side effects over time. In short, the human safety database for the way bodybuilders use ipamorelin is close to empty.

Side Effects Users Commonly Report

With no trials in healthy adults, the best available picture comes from clinics and user reports. These cannot tell you how common each effect is or prove ipamorelin caused it, but the same complaints appear repeatedly:

1Headache, sometimes within an hour of injecting
2Flushing, warmth or a mild head rush
3Dizziness or light-headedness
4Nausea
5Water retention and mild puffiness, especially in the hands and feet
6Tingling or numbness in the fingers
7Increased hunger, which is expected from a ghrelin mimic even though it is milder than with GHRP-6
8Tiredness or, for some people, trouble sleeping
9Redness, itching or a small lump at the injection site

Most of these are described as mild and short-lived. Effects that should not be waved off include spreading redness or pus at an injection site, a rash or hives, swelling of the face or throat, chest pain, severe headache, or symptoms of high blood sugar such as unusual thirst and frequent urination.

Risks That Come From Raising Growth Hormone

Even if ipamorelin itself is "clean," its whole purpose is to raise GH and, through it, IGF-1. Sustained elevation of those hormones has a known side-effect profile from decades of GH research:

1Fluid retention, joint pain and carpal tunnel syndrome. A systematic review of GH in healthy adults found soft tissue swelling and fatigue were significantly more common than with placebo.
2Higher blood sugar. GH works against insulin, so people with prediabetes or diabetes are at particular risk.
3Possible effects on existing cancers. GH and IGF-1 promote cell growth, which is why GH therapy is avoided in people with active cancer. There is no evidence that ipamorelin causes cancer, and no long-term data to rule anything out.
4Acromegaly-type changes with very high, prolonged exposure, such as enlarged hands, feet or jaw. This is theoretical for ipamorelin, since nobody has studied years of use.

Because the GH pulses from ipamorelin are smaller and shorter than from GH injections, these risks are probably lower, but "probably lower" is a guess, not a measurement. The same review found that GH increased lean mass without improving strength, which we explore in CJC-1295 + ipamorelin for muscle growth.

Stacking With CJC-1295 Changes the Picture

Ipamorelin is often combined with CJC-1295, a long-acting GHRH analogue. The combination produces larger and, with CJC-1295 with DAC, much longer GH elevation. That raises the likelihood of the GH-related effects above, particularly water retention, tingling and blood sugar changes. Side-effect reports from people using the stack are more common than from ipamorelin alone. See CJC-1295 for muscle growth for the specific concerns with that peptide.

The Product-Quality Problem

Nearly all ipamorelin used by lifters comes from online vendors labeled "for research use only." These products are not made under pharmaceutical standards and are not checked by any regulator. Independent testing of research peptides has repeatedly found underdosed, mislabeled and contaminated products. For an injectable, that adds risks of infection, bacterial toxins and immune reactions to peptide impurities. Some of the "side effects" attributed to ipamorelin may in fact be reactions to what else is in the vial. We cover the same issue for BPC-157 in BPC-157 side effects.

Is Ipamorelin Legal in 2026?

1FDA: ipamorelin is not approved for any use. FDA's compounding page lists ipamorelin acetate in Category 2 for outsourcing facilities, meaning substances that may present significant safety risks, citing limited safety data. Its status for traditional compounding pharmacies is unresolved while FDA reviews peptide nominations.
2WADA: growth hormone secretagogues, including ipamorelin, are prohibited at all times under section S2 of the Prohibited List. Tested athletes should not use it.
3Selling it as a dietary supplement is illegal in the U.S., which is why it is sold as a research chemical.

Who Should Avoid Ipamorelin

1Anyone with current or past cancer
2People with diabetes or prediabetes, unless under close medical supervision
3People who are pregnant, breastfeeding or trying to conceive
4Athletes subject to drug testing
5Anyone under 18, because GH affects growth plates
6People with heart failure or significant kidney disease, because of fluid retention

The Bottom Line

Ipamorelin probably does have a milder side-effect profile than older GH peptides, and its one controlled human trial found it well tolerated over a week. But "well tolerated for seven days in hospital" is not the same as "safe for months of self-injection," and the risks of raising growth hormone, of stacking with CJC-1295 and of unregulated products are real. If you are considering it for muscle or recovery, the evidence that it works is weaker than the evidence that it is risky. For how it compares with its closest alternatives, read sermorelin vs ipamorelin and tesamorelin vs CJC-1295 vs ipamorelin.

FAQ

Users most often report headache, flushing, dizziness, nausea, water retention, tingling hands, increased hunger and injection-site reactions. Long-term effects have not been studied in healthy adults.

Its safety for bodybuilding use has not been established. One short placebo-controlled trial in surgical patients found it well tolerated, but there are no long-term studies in healthy people, and research-chemical products are unregulated.

Animal studies found that ipamorelin did not significantly raise cortisol or ACTH, unlike GHRP-2 and GHRP-6. This has not been confirmed in long-term human use.

Water retention is one of the most commonly reported effects, especially when stacked with CJC-1295. It is a known effect of raised growth hormone. Ipamorelin can also increase hunger because it mimics ghrelin.

Yes for athletes. WADA prohibits growth hormone secretagogues under section S2 at all times. It is not FDA-approved, and FDA lists it as a Category 2 compounding substance.

Sources

1Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol, 1998
2Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus, Int J Colorectal Dis, 2014
3Systematic review: the effects of growth hormone on athletic performance, Ann Intern Med, 2008
4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, U.S. FDA
52026 Prohibited List, World Anti-Doping Agency
6Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 2011

This article is for information only. It is not medical advice and does not recommend using ipamorelin. Talk to a doctor before using any unapproved substance.